Compass Pathways: There Are Different Scenarios To Be Considered In Clinical, Regulatory, And Commercialization Aug 25, 2026, 1:42 PM ET $CMPS Summary Compass Pathways plc is rated Strong Buy with a $25–$30 fair value, reflecting a significant upside to current levels. Compass Pathways' COMP360 offers a capacity advantage over Spravato, enabling four times more patients per monitored hour and supporting higher peak sales estimates. Regulatory momentum is strong, but timing risk exists due to DEA rescheduling, which could create interim share price volatility. Key upside catalysts include a two-dose label and permanent reimbursement codes, both of which could materially lift the base case valuation. https://seekingalpha.com/article/4940062-compass-pathways-there-are-different-scenarios-to-be-considered-in-clinical-regulatory-and-commercialization?utm
152 views
2 Comments
Nicholas Arvidson@arvidnick · 25d
Going to make money on CMPS!
See the full comment section 👀Sign up for the full Blossom experience!
